Enterprise software developer Damstra Holdings confirms a non-binding bid from technology-focused private equity firm Accel-KKR. Meanwhile, Quadrant Private Equity has exited leakproof apparel company Modibodi for A$140 million ($95.4 million), and Infensa Bioscience, an Australian company that uses spider venom to treat heart attack or stroke, has raised A$23 million ($15.6 million).
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
